Ciltacabtagene Autoleucel

CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.

Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.

A phase 3 trial of ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma met its primary endpoint, according to the agent’s manufacturer.

NEW ORLEANS — In this video perspective, Samer Al Hadidi, MD, MS, FACP, discusses research evaluating G protein–coupled receptor as a new target for therapy in relapsed refractory multiple myeloma.

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

Although chimeric antigen receptor T-cell therapy is approved for treatment of multiple myeloma, commercially available products are limited to patients who received at least four prior lines of therapy.

SALT LAKE CITY — Ciltacabtagene autoleucel induced a 95% overall response rate among patients with multiple myeloma who had early relapse after front-line therapy, according to results of a cohort analysis from the CARTITUDE-2 trial.

Myeloma Awareness Month is observed in March.

The FDA approved ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.

Clinicians who treat patients with chimeric antigen receptor T cells have become adept at identifying and treating acute neurotoxicity, a common adverse event associated with the therapy.